HSP90: Chaperone-me-not

Pathology and Oncology Research

Volumn 19, Issue 4, 2013, Pages 631-640

  Patki, J M ^a   Pawar, S S ^b  

^a CBD Belapur ^*  (India)

^b UNIVERSITY OF MUMBAI   (India)

Author keywords

Cancer hallmarks; Client proteins; Hsp90; Hsp90 inhibitors; Inhibitor classes; Tumor selectivity

Indexed keywords

ALVESPIMYCIN; ANSAMYCIN DERIVATIVE; BORTEZOMIB; CELL CYCLE PROTEIN; CHAPERONE; CISPLATIN; CNF 1010; COUMARIN DERIVATIVE; DIHYDROINDAZOLONE DERIVATIVE; EPIGALLOCATECHIN GALLATE; GANETESPIB; GEDUNIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; ISOFLAVONE DERIVATIVE; ISOXAZOLE DERIVATIVE; PACLITAXEL; POCHONIN A; PROTEIN KINASE; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE; RADICICOL DERIVATIVE; REGULATOR PROTEIN; RETASPIMYCIN; SANSALVAMIDE A; SORAFENIB; STEROID RECEPTOR; TANESPIMYCIN; TRANSCRIPTION FACTOR; TRASTUZUMAB; TRIPTERINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL SURVIVAL; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS; NONHUMAN; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

HSP90 HEAT-SHOCK PROTEINS; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84885180767     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-013-9675-4     Document Type: Review

References (73)

1. Neckers L, Ivy SP (2003) Heat shock protein 90. Curr Opin Oncol 15:419-424
2. Chiosis G, Vilenchik M, Kim J, Solit D (2004) Hsp90: the vulnerable chaperone. Drug Discov Today 9:881-888
3. Goetz MP, Toft DO, Ames MM, Erichman C (2003) The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 14:1169-1176
4. Li Y, Zhang T, Sun D (2009) New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat 12(1-2):17-27
5. Wandinger SK, Richter K, Buchner J (2008) The Hsp90 chaperone machinery. J Biol Chem 283:18473-18477. doi: 10.1074/jbc.R800007200
6. Richter K, Soroka J, Skalniak L, Leskovar A, Hessling M, Reinstein J, Buchner J (2008) Conserved conformational changes in the ATPase cycle of human Hsp90. J Biol Chem 283:17757-17765
7. Pearl LH, Prodromou C, Workman P (2008) The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 410:439-453
8. Dollins ED, Warren JJ, Immormino RM, Gewirth DT (2007) Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones. Mol Cell 28:41-56
9. Travers J, Sharp S, Workman P (2012) HSP90 inhibition: two-pronged exploitation of cancer dependencies. Drug Discov Today 00 (00) (in press)
10. Kasibhatla S, Tseng B (2003) Why target apoptosis in cancer treatment? Mol Cancer Ther 2:573-580
11. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
12. Hanahan D, Weinberg RA (2011) The hallmarks of cancer: the next generation. Cell 144:646-674. doi: 10.1016/j.cell.2011.02.013
13. Bagatell R, Whitesell L (2004) Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 3(8):1021-1030
14. McCarthy MM, Pick E, Kluger Y, Gould-Rothberg B, Lazova R, Camp RL (2008) HSP90 as a marker of progression in melanoma. Ann Oncol 19:590-594
15. Workman P, Burrows F, Neckers L, Rosen N (2007) Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 1113:202-216
16. Sidera K, Patsavoudi E (2009) Extracellular Hsp90: an emerging target for cancer therapy. Curr Signal Transduct Ther 4:51-58
17. Sreedhar AS, Kalmar E, Csermely P, Shen YF (2004) Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett 562:11-15
18. Neckers L (2002) Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8:S55-S61
19. Workman P (2004) Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 206:149-157
20. Pratt WB (1998) The Hsp90 based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors. Proc Soc Exp Biol Med 217:420-434
21. Neckers L (2007) Heat shock protein 90: the cancer chaperone. J Biosci 32:517-530
22. Jaattela M (1999) Escaping cell death: survival proteins in cancer. Exp Cell Res 248:30-43
23. Pasquale EB (2008) Eph-ephrin bi-directional signaling in physiology and disease. Cell 133(1):38-52
24. Bohonowych JE, Gopal U, Issacs JS (2010) Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls. J Oncol. doi: 10.1155/2010/412985
25. Powers MV, Workman P (2006) Targeting the multiple signaling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 13(1):125-135
26. Neckers L (2006) Using natural product inhibitors to validate HSP90 as a molecular target in cancer. Curr Med Chem 6:1163-1171
27. Zhang H, Burrows F (2004) Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 82:488-499
28. Gava LM, Ramos CHI (2009) Human 90Kda Heat shock protein Hsp90 as a target for cancer therapeutics. Curr Chem Biol 3:330-341
29. Issacs JS (2005) Heat shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up? Expert Opin Investig Drugs 14(6):569-589
30. Pecorino L (2008) Molecular biology of cancer. Mechanisms, targets and therpeutics, 2nd edn. Oxford University Press
31. Vilenchik M, Solit D, Basso M, Huezo H, Lucas B, Huazhong H, Rosen N, Spampinato C, Modrich P, Chiosis G (2004) Targeting widerange oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem Biol 11:787-797
32. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ (2003) A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors. Nature 425:407-410
33. Workman P (2003) Auditing the pharmacological accounts for hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol Cancer Ther 2:131-138
34. Workman P (2003) Overview: translating Hsp90 biology into Hsp90 drugs. Curr Cancer Drug Targets 3:297-300
35. Chiosis G, Neckers L (2006) Tumor selectivity of Hsp90 inhibitors - the explanat-ion remains elusive. ACS Chem Biol 1:279-284
36. Maroney AC et al (2006) Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives. Biochemistry 45:5678-5685
37. Solit DB, Rosen N (2006) Hsp90: a novel target for cancer therapy. Curr Top Med Chem 6:1205-1214
38. Xu W, Yuan X, Beebe K et al (2007) Loss of Hsp90 association up-regulates Src dependent ErbB2 activity. Mol Cell Biol 27:220-228
39. Sharma S et al (1998) Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol. Oncogene 16:2639-2645
40. Burlingson JA et al (2007) Development of Novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines. J Org Chem 73:2130-2137
41. Donnelly A, Blagg BSJ (2008) Novobiocin and Hsp90 inhibitors of C terminal nucleotide binding pocket. Curr Med Chem 15(26):2702-2717
42. Wangl Y et al (2010) STA-9090 A small molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs 11(12):1466-1476
43. Hastings JM, Hadden MK, Blagg BSJ (2008) Synthesis and evaluation of Derrubone and select analogues. J Org Chem 73:369-373
44. Nicoll M (2008) XL 888, a novel synthetic, orally bio-available inhibitor of Hsp90. (Presented at the AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, Discovery, Biology, and Clinical Applications, October 21-24, 2008, Geneva, Switzerland. Exelixis Research and Development, Exelixis inc; South San rancisco, CA, USA)
45. Wettstein D et al (2008) MPC-3100: a non-natural product Hsp90 inhibitor with anti-tumor activity in pre-clinical models. 20th EORTC-NCI-AACR, October 21-24 in Geneva, Switzerland
46. Amolins MW, Blagg BSJ (2009) Natural product inhibitors of Hsp90: potential leads for drug discovery. Mini Rev Med Chem 9(2):140-152
47. Vasko RC et al (2010) Mechanistic studies of Sansalvamide A-Amide: an allosteric modulator of Hsp90. ACS Med Chem Lett 1:4-8
48. Brandt GEL et al (2008) Gedunin, a novel Hsp90 inhibitor: semi synthesis of derivatives and preliminary structure activity relationships. J Med Chem 51(20):6495-6502. doi: 10.1021/jm8007486
49. Winssinger N, Barluenga S (2007) Chemistry and biology of resorcyclic acid lactones. Chem Commun:22-36. doi: 10.1039/b610344h
50. Rodriguez RA (2008) Structure-activity of Sansalvamide A derivatives and their apoptotic activity in pancreatic cancer cell line PL-45. Mex Chem Soc 52(3):201-211
51. Yi F, Regan L (2008) A novel class of small molecule inhibitors of Hsp90. ACS Chem Biol 3(10):645-654
52. Sun X, Kenney SC (2010) Hsp90 inhibitors: a potential treatement for latent EBV infection? Cell Cycle 9(9):1665-1666
53. Gorska M et al (2012) Geldanamycin and its derivatives as Hsp90 inhibitors. Front Biosci 17:2269-2277
54. Shapiro G (2011) STA-9090 (Ganetespib) and AT13387. 9th International Symposium on Targeted Cancer Therapies Paris, France
55. Trepel J et al (2010) Targeting the dynamic Hsp90 complex in cancer. Nat Rev Cancer 10:537-549. doi: 10.1038/nrc2887
56. Eskew JD (2011) Development and characterization of novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. BMC Cancer 11:468
57. Mereles D, Hunstein W (2011) Epigallocatechin-3-gallate (EGCG) for clinical trials: more pitfalls than promises? Int J Mol Sci 12:5592-5603. doi: 10.3390/ijms12095592
58. Shelton SN et al (2009) KU135 A novel novobiocin derived C-terminal inhibitor of 90 Kda heat shock protein exerts potent anti-proliferative effects on human luekemic cells. Mol Pharmacol 76(6):1314-1322
59. Chiosis G et al (2002) Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg Med Chem 10:3555-3564
60. Ho N, Li A, Li S, Zhang H (2012) Heat shock protein 90 and role of its chemical inhibitors in treatment of hematologic malignancies. Pharmaceuticals 5:779-801. doi: 10.3390/ph5080779
61. Piper PW, Millson SH (2011) Mechanisms of resistance to Hsp90 inhibitor drugs: a complex mosaic emerges. Pharmaceuticals 4:1400-1422
62. Dymock BW, Barrill X, Brough PA et al (2005) Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem 48:4212-4215
63. Stuhmer T et al (2008) Signalling profile and anti-tumor activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia 22:1604-1612
64. Samuel T et al (2010) AUY922 a novel Hsp90 inhibitor: final results of a first-in-human study in patients with advanced solid malignancies. Am Soc Clin Oncol Ann Meet 46:Abs 2528
65. Okawa Y et al (2009) SNX-2112, a selective hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signalling via Akt and Erk. Blood 113:846-855
66. Richardson et al (2010) Br J Haematol 150:438-445
67. Neckers L, Workman P (2012) Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18(1):64-76. doi: 10.1158/1078-0432.CCR-11-1000
68. Zhang H, Chung D, Yang YC (2006) Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol Cancer Ther 5:1256-1264. doi: 10.1158/1535-7163.MCT-05-0537
69. Smith-Jones PM et al (2006) Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med 47:793-796
70. Solit DB, Chiosis G (2008) Development and applications of Hsp90 inhibitors. Drug Discov Today 13(1/2):38-43
71. Oikonomopoulou K et al (2009) Evaluation of prostate-specific antigen as a novel biomarker of Hsp90 inhibition. Clin Biochem 42(8):16-17
72. Adeela K, Burrows FJ (2009) Hsp90 inhibitors as selective anticancer drugs. Discov Med. http://www.discoverymedicine.com/Adeela-Kamal/2009/07/12/ hsp90-inhibitors-as-selectable-anticancer-drugs/
73. Sliutz G, Karlseder J, Tempfer C, Orel L, Holzer G, Simon M (1996) Drug resistance against gemcitabine and topotecan mediated by constitutive Hsp70 overexpression in vitro: implication of quercetin as sensitizer in chemotherapy. Br J Cancer 74:172-177